Hester Biosciences Ltd
NSE:HESTERBIO

Watchlist Manager
Hester Biosciences Ltd Logo
Hester Biosciences Ltd
NSE:HESTERBIO
Watchlist
Price: 1 599.7 INR 1.25% Market Closed
Market Cap: 13.6B INR

Wall Street
Price Targets

HESTERBIO Price Targets Summary
Hester Biosciences Ltd

There are no price targets for HESTERBIO.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Hester Biosciences Ltd Competitors:
Price Targets
PRTA
Prothena Corporation PLC
117% Upside
CVAC
CureVac NV
6% Upside
VCYT
Veracyte Inc
17% Upside
KRYS
Krystal Biotech Inc
8% Downside
CELC
Celcuity Inc
13% Upside
688363
Bloomage Biotechnology Corp Ltd
10% Upside
MSB
Mesoblast Ltd
30% Upside
ARMP
Armata Pharmaceuticals Inc
46% Upside

Revenue
Forecast

Revenue Estimate
Hester Biosciences Ltd

For the last 13 years the compound annual growth rate for Hester Biosciences Ltd's revenue is 15%.

15%
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Hester Biosciences Ltd

For the last 13 years the compound annual growth rate for Hester Biosciences Ltd's operating income is 9%. The projected CAGR for the next 5 years is 10%.

9%
Past Growth
10%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Hester Biosciences Ltd

For the last 13 years the compound annual growth rate for Hester Biosciences Ltd's net income is 10%.

10%
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-42%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HESTERBIO's stock price target?
Not Available

HESTERBIO doesn't have any price targets made by Wall Street professionals.

What is Hester Biosciences Ltd's Operating Income forecast?
Projected CAGR
10%

For the last 13 years the compound annual growth rate for Hester Biosciences Ltd's operating income is 9%. The projected CAGR for the next 5 years is 10%.

Back to Top